Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study

Piscaglia, FabioFabioPiscagliaIkeda, KenjiKenjiIkedaANN-LII CHENGKudo, MasatoshiMasatoshiKudoIkeda, MasafumiMasafumiIkedaBreder, ValeryValeryBrederRyoo, Baek-YeolBaek-YeolRyooMody, KalgiKalgiModyRen, MinMinRenRamji, ZahraZahraRamjiSung, Max WMax WSung2024-03-292024-03-292024-04-150008543Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/641593Lenvatinib is approved as a first-line treatment for patients with unresectable and/or recurrent hepatocellular carcinoma (HCC). Lenvatinib achieved promising clinical benefits in REFLECT but was associated with clinically significant treatment-emergent hypertension (CSTE-HTN, a grouped term), a common class effect of tyrosine kinase inhibitors. This post hoc analysis assessed the impact of CSTE-HTN on the efficacy and safety of lenvatinib in HCC.enhepatocellular carcinoma; hypertension; lenvatinib; prognosis; statins; treatment outcomeAssociation between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT studyjournal article10.1002/cncr.35185382615212-s2.0-85183047200https://api.elsevier.com/content/abstract/scopus_id/85183047200